Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC

Video

A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.

Transcript:

Robert J. Motzer, MD: The last question on this case, I’ll direct it to Brian. For this patient, assuming that perhaps they have progression in less than 6 months, what is your approach to patients who are progressing on lenvatinib and pembrolizumab in relatively short order after an initial response?

Brian I. Rini, MD: I think, whether their response is long or short, I’m not sure it’d be different. I tend to use cabozantinib second. I think it’s the most active drug that such a patient would not have seen yet. As you’re aware, we don’t yet have level 1 evidence for using immune therapy in sequence, although there are trials ongoing, so I don’t do that off protocol. I tend to give a single-agent TKI [tyrosine kinase inhibitor], realizing that it’s fairly unexciting, but I think that is the default standard, and I tend to give cabozantinib. Unless for some reason, I gave cabozantinib and nivolumab up front, then of course I’d pick a different TKI, but I tend to use the pembrolizumab-based doublets that we’ve talked about.

Robert J. Motzer, MD: Thanks. Just one last question, if this patient had been treated with axitinib plus pembrolizumab and progressed, so they never had a response to axitinib plus pembrolizumab, or a very brief response, Bob, what would you go to next in that sort of a patient?

Robert S. Alter, MD: I know there are still no level 1 data, but people have started talking about giving ipilimumab plus nivolumab a bit. I agree with Brian, I think cabozantinib seems to be a very good second-line agent. Yes, at the same time too, based upon the data from len/eve [lenvatinib and everolimus], it seems to be very good in regard to a second-line regimen. We’ve seen dramatic responses, progression-free survival data, and durability. Tolerability seems to be a bit of a concern, but adjusting the doses as we have just discussed seems to be very appropriate. And again, you do get exposure to an mTOR [inhibitor] that we have not seen before, so sometimes giving a different mechanism may offer a better response in patients who failed IO [immunotherapy]/TKI therapy.

Robert J. Motzer, MD: Thanks very much for that insight. I think it’s a great case and a great discussion.

Transcript edited for clarity.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content